Bictegravir
BMD
Prism Health North TexasSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the BMD cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TENOFOVIR DISOPROXIL FUMARATE Prism Health North Texas | Phase 3 | B |
Doravirine Prism Health North Texas | Phase 3 | B |
Lamivudine Prism Health North Texas | Phase 3 | B |
(±)-FTC Prism Health North Texas | Phase 3 | B |
Tenofovir Alafenamide Prism Health North Texas | Phase 3 | B |
Same molecule, other indications
Bictegravir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →